Prostaglandin Analogs in the Treatment of Glaucoma

Seminars in Ophthalmology 14, 114-123

DOI: 10.3109/08820539909061464

Citation Report

#	Article	IF	CITATIONS
1	Induction of Tyrosinase Gene Transcription in Human Iris Organ Cultures Exposed to Latanoprost. JAMA Ophthalmology, 2001, 119, 853.	2.4	29
2	Effects of Isopropyl Unoprostone, Latanoprost, and Prostaglandin E ₂ on Acute Rise of Aqueous Flare in Pigmented Rabbits. Ophthalmic Research, 2002, 34, 90-93.	1.9	8
3	Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma. American Journal of Ophthalmology, 2002, 134, 552-559.	3.3	39
4	Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients. Acta Ophthalmologica, 2003, 81, 474-479.	0.3	52
5	Patient Persistency with ocular prostaglandin therapy: A population-based, retrospective study. Clinical Therapeutics, 2003, 25, 1172-1185.	2.5	67
6	Conjunctival Hyperemia and the Use of Topical Prostaglandins in Glaucoma and Ocular Hypertension. Journal of Ocular Pharmacology and Therapeutics, 2003, 19, 23-35.	1.4	73
7	Four Years Later: A Clinical Update on Latanoprost. European Journal of Ophthalmology, 2003, 13, 162-175.	1.3	31
8	Trends in Glaucoma Surgery before and after the Introduction of New Topical Glaucoma Pharmacotherapies. Journal of Glaucoma, 2004, 13, 221-226.	1.6	58
9	Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes. Eye, 2005, 19, 784-787.	2.1	31
10	Systemic adverse effects of topical ocular treatments. Presse Medicale, 2005, 34, 589-595.	1.9	39
11	Acute effects of glaucoma medications on rat intraocular pressure. Experimental Eye Research, 2005, 80, 207-214.	2.6	46
12	Neuroprotective effect of latanoprost on rat retinal ganglion cells. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 1003-1009.	1.9	37
13	Chapter 13 Outflow Signaling Mechanisms and New Therapeutic Strategies for the Control of Intraocular Pressure. Current Topics in Membranes, 2008, 62, 427-469.	0.9	1
14	Long-term Effects of Latanoprost Monotherapy on Intraocular Pressure in Japanese Glaucoma Patients. Journal of Glaucoma, 2008, 17, 662-666.	1.6	15
15	The effect of latanoprost on ocular blood flow. International Ophthalmology, 2009, 29, 19-26.	1.4	14
16	Trends in Glaucoma Medication Expenditure. JAMA Ophthalmology, 2011, 129, 1345.	2.4	17
17	The biology, pathology and therapeutic use of prostaglandins in the eye. Clinical Lipidology, 2011, 6, 577-591.	0.4	9
18	Toxicologic Pathology of the Eye: Histologic Preparation and Alterations of the Anterior Segment. Molecular and Integrative Toxicology, 2012, , 159-217.	0.5	5

#	Article	IF	CITATIONS
19	A Case of Herpetic Simplex Keratitis after Application of 0.015% Tafluprost Eye Drops. Journal of Korean Ophthalmological Society, 2013, 54, 1950.	0.2	1
20	Biotechnological approach towards a highly efficient production of natural prostaglandins. Biotechnology Letters, 2014, 36, 2193-2198.	2.2	2
21	Phospholipid profiles of control and glaucomatous human aqueous humor. Biochimie, 2014, 101, 232-247.	2.6	36
22	Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma. American Journal of Ophthalmology, 2016, 163, 70-74.e1.	3.3	17
23	Segmental outflow of aqueous humor in mouse and human. Experimental Eye Research, 2017, 158, 59-66.	2.6	26
24	<p>Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment</p> . International Journal of Nanomedicine, 2020, Volume 15, 5745-5765.	6.7	31
25	NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances $TGF\hat{l}^22$ -Induced Outflow in HTM/HSC Constructs., 2021, 62, 17.		7
26	Latanoprost İçeren İki Çoklu Doz Göz Damlasının Fiziksel Özelliklerinin ve Yıllık Maliyetlerinin Karşılaştırılması. Akdeniz Medical Journal, 0, , 153-157.	0.1	0
27	Morphological and functional changes in experimental ocular hypertension and role of neuroprotective drugs. Histology and Histopathology, 2007, 22, 1399-411.	0.7	16
28	Trends in development and quality assessment of pharmaceutical formulations - $F2\hat{l}\pm$ analogues in the glaucoma treatment. European Journal of Pharmaceutical Sciences, 2023, 180, 106315.	4.0	5
29	A comparative evaluation of the efficacy and safety of Latanoprost-Optic and Xalatan used as monotherapy and combined with Dorzolamide-Optic for primary open-angle glaucoma under clinical practice conditions. Rossiiskii Oftal'mologicheskii Zhurnal, 2023, 16, 135-141.	0.4	0